Multivesicular liposomes with controlled release of active agent

Details Multivesicular liposomes with controlled release of active agent Multivesicular liposomes with controlled release of active agent

1998-02-05

2000-06-06

Kishore, Gollamudi S.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

264 41, 264 43, 264 46, 436829, 935 54, A61K 9127

Patent

active

060715340

ABSTRACT:
Disclosed are multivesicular liposomes containing biologically active substances, and having defined size distribution, adjustable average size, adjustable internal chamber size and number, and a modulated release of the biologically active substance. The liposomes are made by a process comprising dissolving a lipid component in volatile organic solvents, adding an immiscible aqueous component containing at least one biologically active substance to be encapsulated, and adding to either or both the organic solvents and the lipid component, a hydrochloride effective to control the release rate of the biologically active substance from the multivesicular liposome. A water-in-oil emulsion is made from the two components, the emulsion is immersed into a second aqueous component, and then divided into small solvent spherules which contain even smaller aqueous chambers. The solvents arc finally removed to give an aqueous suspension of multivesicular liposomes encapsulating biologically active substances.

REFERENCES:
patent: 4078052 (1978-03-01), Papahadjopoulos
patent: 4089801 (1978-05-01), Schneider
patent: 4145410 (1979-03-01), Sears
patent: 4224179 (1980-09-01), Schneider
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4310506 (1982-01-01), Baldeschwieler et al.
patent: 4394372 (1983-07-01), Taylor
patent: 4522803 (1985-06-01), Lenk et al.
patent: 4588578 (1986-05-01), Fountain et al.
patent: 4599227 (1986-07-01), Dees et al.
patent: 4610868 (1986-09-01), Fountain et al.
patent: 4752425 (1988-06-01), Martin et al.
patent: 4769250 (1988-09-01), Forssen
patent: 4771612 (1988-09-01), Janoff
patent: 4781871 (1988-11-01), West, III et al.
patent: 4797285 (1989-01-01), Barenholz et al.
patent: 4814270 (1989-03-01), Piran
patent: 4920016 (1990-04-01), Allen et al.
patent: 4975282 (1990-12-01), Cullis
patent: 5000959 (1991-03-01), Iga et al.
patent: 5021200 (1991-06-01), Vanlerberghe et al.
patent: 5077056 (1991-12-01), Bally et al.
patent: 5204111 (1993-04-01), Hope et al.
patent: 5211955 (1993-05-01), Legros et al.
patent: 5334381 (1994-08-01), Unger et al.
patent: 5334391 (1994-08-01), Clark et al.
patent: 5422120 (1995-06-01), Kim
patent: 5576017 (1996-11-01), Kim
patent: 5723147 (1998-03-01), Kim
"Topology of Multivesicular Liposomes, a Model Biliquid Foam," Langmuir 12:4704-4708, 1996, by M.S. Spencer et al.
Crommelin, Internat. J. Pharmaceutics 16 (1983) p.79.
Aldrich, Che Comp Inc. p. 369.
Macly et al., BBA 730, 313-320 (1983).
Huang, Biochemistry, 8:334-352, 1969, "Studies on Phosphatidylcholine Vesicles formation and Physical characteristics."
Bang, M. Mol. Bio., 13-238-252, 1965, "Diffusion of univalent ions across the lamellae of swollen phospholipids."
Szoka, et al., Ann. Rev. Biophys. Bioeng., 9:465-508, 1980, "Comparative properties and methods of preparation of lipid vesicles (liposomes)."
Shakiba, et al., Investigative ophthalmology and visual Science, 34(10):2903-10, 1993 Sep., "Evaluation of retinal toxicity and liposome encapsulation of the Anti-CMV Drug 2'-nor-cyclic GMP."
Frucht-Perry, et al., Cornea, 11(5):393-7, 1992 Sep., "Fibrin-enmeshed tobramycin liposomes: single application topical therapy of pseudomonas . . . ".
Assil, et al., Investigative Ophthalmology and Visual Science, 32(13):3216-20, Dec. 1991, "Tobramycin liposomes. Single subconjunctival therapy of . . . ".
Assil, et al., Investigative Ophthalmology and Visual Science, 32(11):2891-7, Oct. 1991, Liposome suppression of proliferative vitreoretinopathy. Rabbit . . . .
Turski, et al., Magnetic Resonance in Medicine, 7(2):184-96, 1988 Jun. 1988, "Magnetic resonance imaging of rabbit brain after intracarotid injection . . .".
Skuta, et al., American Journal of Ophthalmology, 103(5):714-16, May 15 1987 "Filtering surgery in owl monkeys treated with the antimetabolite . . .".
Assil, et al., Archives of Ophthalmology, 105(3):400-3, Mar. 1987, "Multivesicular liposomes. Sustained release of the antimetabolite . . .".
Barbet, et al., Biochimica et Biophysica Acta, 772(3):347-56, May 30 1984, "Weat acid-induced release of liposome-encapsulated carboxyfluorescein".
Kim, et al., Biochim. Biophys. Acta, 646:1, 1981, "Preparation of cell-size unilamellar liposomes with high captured volume and defined size . . .".
Kim, et al., Biochim. Biophys. Acta, 728:339-348, 1983, "Preparation of multivesicular liposomes".
Kim, et al., Biochim. Biophys. Acta, 793:801, 1985, "Preparation of multilamellar vesicles of defined size-distribution by solvent-spherule . . .".
Kim, et al., Cancer Treat. Rep., 71:705-711, 1987, "Multivesicular liposomes containing cytarabine entrapped in the presence of . . .".
Kim, et al., Cancer Research, 47:3935-3937, 1987, "Multivesicular Liposomes Containing cytosine arabinoside for slow-release intrathecal therapy."
Kim, et al., Cancer Treat Rep. 71:447-450, 1987, "Multivesicular liposomes containing cytosine arabinoside for slow-release . . .".
Kim, et al., Cancer Chemother Pharmacology, 19:307-310, 1987, "Modulation of the peritoneal clearance of liposomal ara-C by blank liposomes."
Roy, et al., Cancer Chemother. Pharm., 28:105-108, 1991, "Multivesicular liposomes containing bleomycin for subcutaneous administration."
Kim, et al., Reg. Cancer Treat., 2:170-173, 1989, "Intratumoral chemotherapy with multivesicular liposomes containing 1-b-D-arabino . . .".
Kim, et al., J. Inf. Dis., 162:750-752, 1990, "Multivesicular liposomes for CSF delivery of retroviral agent DDC."
Chamberlain, et al., Archives of Neurol, 50(3):261-264, 1993, "Treatment of leptomeningeal metastasis with intraventricular administration of . . .".
Chatelut, et al., Cancer Them. Pharmacol., 32:179-182, 1993, "A slow-release methotrexate formulation for inrathecal chemotherapy."
Russack, et al., Ann. Neurol., 34:108-112, 1993, "Quantitative cerebrospinal fluid cytology in patients receiving intracavitary chemotherapy."
Kim, et al., J. Clin. Oncol., 11:2186-2193, 1993, "Extended cerebrospinal-fluid cytarabine exposure following intrathecal administration of DTC 101."
Kim, Drugs, 46:618-638, 1993, "Liposomes as carriers of cancer chemotherapy: a review."
Kim, Kim, Kim, Cancer Chemother. Pharmacol., 33:187-190, 1993, "Extended-release formulation of morphine for subcutaneous administration. "
Ishii, Liposome Technology, 1:111-121, 1993, "Production and Size Control of large unilamellar liposomes by emulsification."
Cullis, et al., Phospholipids and Cellular Regulation, 1:65-123, 1985, "Structural properties and functional roles of phospholipids in . . .".
Bonetti, et al., Cancer Chemotherapy and Pharmacology, In Press, 1993, "An extended-release formulation of methotrexate for subcutaneous . . . ".
Kim, et al., Cancer Res., 53:1596-1598, 1993 "Prolongation of drug action in CSF by encapsulation into multivesicular liposomes."

Affiliated with

Also associated with

Rating

Multivesicular liposomes with controlled release of active agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multivesicular liposomes with controlled release of active agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivesicular liposomes with controlled release of active agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2211266